UBS’s Pacira BioSciences PCRX Stock Holding History

UBS’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$1.9M	Sell	19,624 -5,776	-23%	-$562K	﹤0.01%	2956
2014 Q2	$2.33M	Buy	25,400 +14,532	+134%	+$1.11M	﹤0.01%	2730
2014 Q1	$761K	Sell	10,868 -7,556	-41%	-$514K	﹤0.01%	3778
2013 Q4	$1.06M	Sell	18,424 -8,510	-32%	-$447K	﹤0.01%	3478
2013 Q3	$1.29M	Sell	26,934 -15,106	-36%	-$550K	﹤0.01%	3045
2013 Q2	$1.22M	Buy	+42,040	New	+$1.22M	﹤0.01%	3110

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

UBS's PCRX Position: Q3 2014 in Review

UBS reduced its Pacira BioSciences (PCRX) stake by 23% in Q3 2014, selling an estimated $562K and leaving 19,624 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2956.

UBS first reported a position in PCRX in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.33M in Q2 2014. 208 funds tracked by Wall St. Rank hold PCRX as of Q3 2014.

UBS held 19,624 shares of Pacira BioSciences worth $1.9M as of Q3 2014.
UBS sold 5,776 Pacira BioSciences shares in Q3 2014, an estimated $562K.
Pacira BioSciences made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2956 holding.
UBS first reported a position in Pacira BioSciences in Q2 2013 and has held it in 6 quarters since.
UBS's Pacira BioSciences position peaked at $2.33M in Q2 2014.
208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.